LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 81

Search options

  1. Book ; Conference proceedings: Recent trends in the discovery, development and evaluation of antifungal agents

    Fromtling, Robert A.

    proceedings of an International Telesymposium [on Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents], May 1987

    1987  

    Event/congress International Telesymposium on Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents (1987)
    Author's details chairman R. A. Fromtling
    Keywords Antifungal Agents / congresses ; Antimykotikum ; Forschung und Entwicklung ; Kongress ; 1987
    Subject Forschung ; FuE ; Research and development ; F&E ; R&D ; Entwicklung
    Size 641 S. : Ill., graph. Darst.
    Publisher Prous
    Publishing place Barcelona
    Publishing country Spain
    Document type Book ; Conference proceedings
    HBZ-ID HT003409735
    ISBN 84-398-8760-4 ; 978-84-398-8760-7
    Database Catalogue ZB MED Nutrition, Environment, Agriculture

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Shelf markLoan statusLocation
    908/227 order for loan Geschlossenes Magazin (U2)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Book ; Conference proceedings: Recent trends in the discovery, development and evaluation of antifungal agents

    Fromtling, Robert A.

    proceedings of an International Telesymposium [on Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents], May 1987

    1987  

    Event/congress International Telesymposium on Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents (1987)
    Author's details chairman R. A. Fromtling
    Keywords Antifungal Agents / congresses ; Antimykotikum ; Forschung und Entwicklung ; Kongress ; 1987
    Subject Forschung ; FuE ; Research and development ; F&E ; R&D ; Entwicklung
    Size 641 S. : Ill., graph. Darst.
    Publisher Prous
    Publishing place Barcelona
    Publishing country Spain
    Document type Book ; Conference proceedings
    HBZ-ID HT003409735
    ISBN 84-398-8760-4 ; 978-84-398-8760-7
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    1989 A 5608 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Human mycoses and advances in antifungal therapy.

    Fromtling, R A

    Drug news & perspectives

    2001  Volume 14, Issue 3, Page(s) 181–192

    Abstract: The 11th Focus on Fungal Infections meeting was held in Washington, D.C., U.S.A., March 1416, 2001. At the conference, there were well-attended sessions that focused on the pathogenesis and therapy of fungal disease. This report focuses on new ... ...

    Abstract The 11th Focus on Fungal Infections meeting was held in Washington, D.C., U.S.A., March 1416, 2001. At the conference, there were well-attended sessions that focused on the pathogenesis and therapy of fungal disease. This report focuses on new information on fungal incidence and pathogenesis as well as on the in vitro and clinical experience of established antifungal drugs (fluconazole, itraconazole, amphotericin B, liposomal formulations of amphotericin B, terbinafine) and the newer antifungal compounds approved for use (e.g., caspofungin) and in development (the new-generation azoles: voriconazole, posaconazole, ravuconazole, and the candins, micafungin and anidulafungin).
    Language English
    Publishing date 2001-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 885125-6
    ISSN 2013-0139 ; 0214-0934
    ISSN (online) 2013-0139
    ISSN 0214-0934
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2393: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Progress in antibacterial and antifungal chemotherapy.

    Fromtling, R A

    Drug news & perspectives

    2000  Volume 13, Issue 6, Page(s) 366–377

    Abstract: The European Society of Clinical Microbiology and Infectious Diseases sponsored the 10th European Congress on Clinical Microbiology and Infectious Diseases in Stockholm, Sweden, May 28-31, 2000. At the ECMID, well-attended sessions were held which ... ...

    Abstract The European Society of Clinical Microbiology and Infectious Diseases sponsored the 10th European Congress on Clinical Microbiology and Infectious Diseases in Stockholm, Sweden, May 28-31, 2000. At the ECMID, well-attended sessions were held which focused on the pathogenesis and therapy of viral, bacterial and fungal diseases. This report focuses on new information on resistance to antibacterial agents, including data from recent surveillance studies, and the in vitro and investigational clinical activity of new antibacterial (moxifloxacin, telithromycin) and antifungal (fluconazole, itraconazole, voriconazole, amphotericin B, liposomal formulations of amphotericin B, terbinafine and the candins) drugs.
    Language English
    Publishing date 2000-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 885125-6
    ISSN 2013-0139 ; 0214-0934
    ISSN (online) 2013-0139
    ISSN 0214-0934
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2393: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Advances in antifungal chemotherapy.

    Fromtling, R A

    Drug news & perspectives

    1998  Volume 11, Issue 9, Page(s) 582–595

    Abstract: The American Society for Microbiology sponsored the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), a premier annual scientific conference, in San Diego, California, September 24-27, 1998. At the ICAAC several sessions were ...

    Abstract The American Society for Microbiology sponsored the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), a premier annual scientific conference, in San Diego, California, September 24-27, 1998. At the ICAAC several sessions were held which focused on the pathogenesis of fungal disease, the in vitro susceptibility testing of new azole (voriconazole, Syn-2869, SCH-56592, carbendazim), echinocandin-like (FK-463, LY-303366, MK-0991), polyene (patricins) and established antifungal agents (fluconazole, itraconazole, amphotericin B, nystatin, terbinafine), the experimental in vivo activity of these new antifungal drugs in various animal models of fungal disease, and the clinical activity of fluconazole, itraconazole and liposomal amphotericin B formulations.
    Language English
    Publishing date 1998-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 885125-6
    ISSN 2013-0139 ; 0214-0934
    ISSN (online) 2013-0139
    ISSN 0214-0934
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2393: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Medical mycology and current trends in antifungal chemotherapy.

    Fromtling, R A

    Drug news & perspectives

    1998  Volume 11, Issue 5, Page(s) 310–319

    Abstract: The Medical Mycological Society of the Americas (MMSA) and the American Society for Microbiology (ASM) are both premier scientific organizations which held their annual conferences in Atlanta, Georgia, May 17-21, 1998. The MMSA scientific session focused ...

    Abstract The Medical Mycological Society of the Americas (MMSA) and the American Society for Microbiology (ASM) are both premier scientific organizations which held their annual conferences in Atlanta, Georgia, May 17-21, 1998. The MMSA scientific session focused on the role of animal models in drug development and on the immunology and molecular biology of the medically important fungi. The use of current molecular tools in identifying new fungal targets for the development of antifungal agents and for the study of fungal epidemiology was reviewed. At the ASM, several sessions were held which focused on the pathogenesis of fungal disease, the in vitro susceptibility testing of new (voriconazole, SCH-56592, LY-303366, metalloporphyrins) and established antifungal agents, the experimental in vivo activity of new antifungal drugs in various animal models of fungal disease and pediatric mycology; the clinical activity of fluconazole, itraconazole, liposomal nystatin and liposomal amphotericin B formulations was also reviewed.
    Language English
    Publishing date 1998-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 885125-6
    ISSN 2013-0139 ; 0214-0934
    ISSN (online) 2013-0139
    ISSN 0214-0934
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2393: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Human mycoses and current antifungal therapy.

    Fromtling, R A

    Drug news & perspectives

    1998  Volume 11, Issue 3, Page(s) 185–191

    Abstract: The Focus on Fungal Infections meeting has become a popular conference for specialists in medical mycology and antifungal chemotherapy. Highlights of the 8th meeting are reported, with a focus on infection and therapy. Although the incidence of mycoses ... ...

    Abstract The Focus on Fungal Infections meeting has become a popular conference for specialists in medical mycology and antifungal chemotherapy. Highlights of the 8th meeting are reported, with a focus on infection and therapy. Although the incidence of mycoses has increased, the identification of these fungal etiologic agents remains difficult. Mucosal candidiasis caused by endogenous Candida albicans and Candida species remains the most common fungal manifestation in HIV-infected patients, while systemic infection by Aspergillus species also has increased in HIV patients. Two presenters at the meeting debated whether fungal infections in AIDS patients are becoming less common and less important. Various strategies for antifungal therapy in AIDS or HIV-positive patients were presented. Most fungal infections in solid organ transplant patients are due to Candida species or Aspergillus species; however, dematiaceous (dark-pigmented) fungi are becoming more common fungal pathogens in these patients. Antifungal therapy remains difficult in this patient group. The meeting included an overview of the current status of diagnosing fungal infections through serodiagnostic techniques. If properly validated, serology can be useful in fungal diagnosis since antigens and antibodies are easier to detect than the invading organism. Premature infants are at high risk for developing invasive fungal infections. Antifungal drugs have not been tested in controlled clinical trials in these patients, thus therapy is accomplished using adult treatment regimens and anecdotal experience. As regards the new lipid-based formulations of amphotericin B, published clinical studies are only now appearing in the literature and these reports suggest that the new formulations have reduced toxicity and comparable efficacy compared to conventional amphotericin B under various clinical conditions. Correlation of minimum inhibitory concentration (MIC) values with clinical response to therapy is beginning to emerge. Two fungal cell wall-active compounds have recently entered clinical trials: an echinocandin and the chitin-synthesis inhibitor nikkomycin Z. Pradimycin and analogues have been studied through experimental animal models with good success; however, phase I clinical trials suggested drug-related toxicities and development was stopped. New molecular targets also are being investigated in antifungal therapy.
    Language English
    Publishing date 1998-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 885125-6
    ISSN 2013-0139 ; 0214-0934
    ISSN (online) 2013-0139
    ISSN 0214-0934
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2393: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Overview of medically important antifungal azole derivatives.

    Fromtling, R A

    Clinical microbiology reviews

    1988  Volume 1, Issue 2, Page(s) 187–217

    Abstract: Fungal infections are a major burden to the health and welfare of modern humans. They range from simply cosmetic, non-life-threatening skin infections to severe, systemic infections that may lead to significant debilitation or death. The selection of ... ...

    Abstract Fungal infections are a major burden to the health and welfare of modern humans. They range from simply cosmetic, non-life-threatening skin infections to severe, systemic infections that may lead to significant debilitation or death. The selection of chemotherapeutic agents useful for the treatment of fungal infections is small. In this overview, a major chemical group with antifungal activity, the azole derivatives, is examined. Included are historical and state of the art information on the in vitro activity, experimental in vivo activity, mode of action, pharmacokinetics, clinical studies, and uses and adverse reactions of imidazoles currently marketed (clotrimazole, miconazole, econazole, ketoconazole, bifonazole, butoconazole, croconazole, fenticonazole, isoconazole, oxiconazole, sulconazole, and tioconazole) and under development (aliconazole and omoconazole), as well as triazoles currently marketed (terconazole) and under development (fluconazole, itraconazole, vibunazole, alteconazole, and ICI 195,739).
    MeSH term(s) Animals ; Antifungal Agents ; Azoles/pharmacology ; Humans
    Chemical Substances Antifungal Agents ; Azoles
    Language English
    Publishing date 1988-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 645015-5
    ISSN 1098-6618 ; 0893-8512
    ISSN (online) 1098-6618
    ISSN 0893-8512
    DOI 10.1128/CMR.1.2.187
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2409: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Chemiluminescence and lymphocyte transformation of immune cells in experimental uremia.

    Fromtling, R A

    Nephron

    1986  Volume 43, Issue 1, Page(s) 78

    MeSH term(s) Animals ; Immune System/cytology ; Luminescent Measurements ; Lymphocyte Activation ; Mice ; Uremia/immunology
    Language English
    Publishing date 1986
    Publishing country Switzerland
    Document type Letter
    ZDB-ID 207121-6
    ISSN 1423-0186 ; 2235-3186 ; 1660-8151 ; 0028-2766
    ISSN (online) 1423-0186 ; 2235-3186
    ISSN 1660-8151 ; 0028-2766
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 169: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: L-671,329, a new antifungal agent. III. In vitro activity, toxicity and efficacy in comparison to aculeacin.

    Fromtling, R A / Abruzzo, G K

    The Journal of antibiotics

    1989  Volume 42, Issue 2, Page(s) 174–178

    Abstract: L-671,329 is a novel, echinocandin-like natural product that possesses potent anti-Candida activity, including activity against Candida parapsilosis. The in vitro MICs of L-671,329 were comparable to aculeacin against 18 yeasts and three filamentous ... ...

    Abstract L-671,329 is a novel, echinocandin-like natural product that possesses potent anti-Candida activity, including activity against Candida parapsilosis. The in vitro MICs of L-671,329 were comparable to aculeacin against 18 yeasts and three filamentous fungi in an agar dilution assay. L-671,329 lysed mouse red blood cells (RBCs) at a concentration of 400 micrograms/ml, but not at 50 or 12.5 micrograms/ml. Aculeacin lysed RBCs at 400 and 50 micrograms/ml. L-671,329 significantly prolonged survival of mice infected with Candida albicans (ED50 3.38 mg/kg) following twice-daily intraperitoneal dosing for five consecutive days. The prolongation observed was greater than that seen with aculeacin therapy (ED50 6.44 mg/kg). No acute or chronic toxicities of L-671,329 or aculeacin (as measured by mortality) were detected at a concentration of 100 mg/kg following intraperitoneal administration (TD50 greater than 100 mg/kg). Both L-671,329 and aculeacin eradicated cells of C. albicans from the kidneys of infected mice. L-671,329 eradicated the yeast at therapeutic concentrations of 12.5 to 100 mg/kg. Aculeacin eradicated yeast cells at therapy concentrations of 25 to 100 mg/kg. L-671,329 has potential as an anti-Candida compound.
    MeSH term(s) Animals ; Anti-Bacterial Agents ; Antifungal Agents/pharmacology ; Antifungal Agents/toxicity ; Candida albicans/drug effects ; Candidiasis/drug therapy ; Candidiasis/microbiology ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical ; Echinocandins ; Erythrocytes/drug effects ; Female ; Hemolysis/drug effects ; Kidney/microbiology ; Liver/drug effects ; Mice ; Microbial Sensitivity Tests ; Peptides ; Peptides, Cyclic/pharmacology ; Peptides, Cyclic/toxicity
    Chemical Substances Anti-Bacterial Agents ; Antifungal Agents ; Echinocandins ; Peptides ; Peptides, Cyclic ; pneumocandin A(0) (120300-08-5) ; aculeacin A (58814-86-1)
    Language English
    Publishing date 1989-02
    Publishing country Japan
    Document type Comparative Study ; Journal Article
    ZDB-ID 390800-8
    ISSN 1881-1469 ; 0021-8820 ; 0368-3532
    ISSN (online) 1881-1469
    ISSN 0021-8820 ; 0368-3532
    DOI 10.7164/antibiotics.42.174
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 207: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top